{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:01:03Z","timestamp":1789275663622,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>The National Centralized Volume-Based Procurement policy for drugs has effectively reduced drug prices but has raised concerns regarding quality and safety. To address these issues, adverse drug reactions (ADR) are monitored through a national system. As the policy stabilizes, real-world data (RWD) may improve, making ongoing monitoring crucial for studies and assessments. This study monitored 13 drug types from batches 1 to 8 across 39 provincial hospitals, supplied by 12 marketing authorization holders. We compared tracking data with the \u201cNational Adverse Drug Reaction Monitoring System\u201d to analyze reporting rates of ADR and identify risk signals for rational drug use in practice. The monitoring period was from May to December 2023, and routine data from 2019 to 2022 were analyzed using descriptive statistics and comparative methods. A safety evaluation of 13 drug types across 39 hospitals revealed ADR rates ranging from 0 to 4.58% and serious reactions ranging from 0 to 1.97%, with 4 identified risk signals. In comparison, routine monitoring indicated lower rates: 0 to 1.20% for ADR and 0 to 0.80% for serious reactions, with one risk signal. Despite these differences, the ADR risks associated with all drugs were manageable, with no unexpected events exceeding label listings. These findings suggest that the safety of domestic generic drugs is comparable to that of originator drugs, supporting the effectiveness of China\u2019s centralized procurement policy. This study aims to enhance coordination among the healthcare, insurance, and pharmaceutical sectors by improving the supervision of drug procurement and RWD research. It emphasizes the need for rigorous monitoring to address safety concerns.<\/jats:p>","DOI":"10.1097\/md.0000000000046379","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:02Z","timestamp":1765814522000},"page":"e46379","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Research and practice on key drug safety monitoring under the normalization of centralized procurement: A case study of 13 selected drugs in a Province"],"prefix":"10.1097","volume":"104","author":[{"given":"Guirong","family":"Ding","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8563-2540","authenticated-orcid":false,"given":"Jinxi","family":"Ding","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s12913-024-10964-7","article-title":"The impacts of National Centralized Drug Procurement Policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.","volume":"24","author":"Li","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"1405197","DOI":"10.3389\/fpubh.2024.1405197","article-title":"National centralized drug procurement and health care expenditure of households \u2013 micro-evidence from CFPS.","volume":"12","author":"Li","year":"2024","journal-title":"Front Public Health"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"804237","DOI":"10.3389\/fphar.2021.804237","article-title":"Impact of the pilot volume-based drug purchasing policy in China: interrupted time-series analysis with controls.","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"1227102","DOI":"10.3389\/fpubh.2023.1227102","article-title":"Impact of China\u2019s national centralized drug procurement policy on pharmaceutical enterprises\u2019 financial performance: a quasi-natural experimental study.","volume":"11","author":"Sun","year":"2023","journal-title":"Front Public Health"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s11096-024-01767-1","article-title":"Impact and implications of national centralized drug procurement in China.","volume":"46","author":"Wang","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"1185356","DOI":"10.3389\/fpubh.2023.1185356","article-title":"The impact of drug shortages on drug prices: evidence from China.","volume":"11","author":"Hu","year":"2023","journal-title":"Front Public Health"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1115650","DOI":"10.3389\/fpubh.2023.1115650","article-title":"Impact of the COVID-19 epidemic on medical product imports from China from outbreak to stabilization: monthly panel data regression and instrumental variable test.","volume":"11","author":"Pu","year":"2023","journal-title":"Front Public Health"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"1345672","DOI":"10.3389\/fphar.2024.1345672","article-title":"Assessment of the implementation of accelerated drug marketing registration procedures for antineoplastic and immunomodulating agents in China: based on 2016\u20132022 review data.","volume":"15","author":"Lan","year":"2024","journal-title":"Front Pharmacol"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","article-title":"The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis.","volume":"40","author":"Rolfes","year":"2017","journal-title":"Drug Saf"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"923939","DOI":"10.3389\/fphar.2022.923939","article-title":"Adverse drug reactions and correlations with drug\u2013drug interactions: a retrospective study of reports from 2011 to 2020.","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"1386533","DOI":"10.3389\/fphar.2024.1386533","article-title":"The impact of Chinese volume-based procurement on pharmaceutical market concentration.","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"1233491","DOI":"10.3389\/fphar.2023.1233491","article-title":"Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11096-018-0693-x","article-title":"Pharmacovigilance in China: development and challenges.","volume":"40","author":"Zhao","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"2417410","DOI":"10.1080\/20523211.2024.2417410","article-title":"Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study.","volume":"17","author":"Cheng","year":"2024","journal-title":"J Pharm Policy Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:04Z","timestamp":1765814524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":14,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046379","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-08-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}